氨磺必利与阿立派唑治疗女性精神分裂症对照研究  

A Case Controll Study of Amisulpride and Aripiprazole for the Treatment of Female Schizophrenia Patients

作　　者：张海艳[1] 王锦华 杨亚妮[1] 刘晓凤[1] 刘祥芹[1] 王锦[1] 

机构地区：[1]西安市精神卫生中心,西安710061 [2]陕西省交通医院

出　　处：《国际精神病学杂志》2016年第3期418-420,共3页Journal Of International Psychiatry

摘　　要：目的比较氨磺必利与阿立派唑治疗女性精神分裂症的临床疗效。方法选取2013年1月~2014年12月期间我院收治的女性精神分裂患者80名,运用随机信封法分为氨磺必利组和阿立派唑组,每组各40例,分别采用氨磺必利和阿立派唑单药治疗,8周为1疗程,分别于治疗前1天,治疗开始后第4周和第8周观察评价相关治疗指标。结果氨磺必利和阿立派唑均可显著降低精神分裂患者阳性和阴性症状量表（PANSS）评分（P〈0.05）,但是在降低的幅度上两者差异没有统计学意义（P〉0.05）;氨磺必利治疗可导致患者血清泌乳素含量升高、心电图QT间期延长,而阿立派唑治疗对此几乎没有影响。而且阿立派唑组患者总的不良反应发生率显著低于氨磺必利（P〈0.05）。结论氨磺必利和阿立哌唑均可有效治疗女性精神分裂症,阿立派唑相比于氨磺必利是一种更安全的女性抗精神分裂药物。Objective To compare the efficacy and adverse effect respectively of Amisulpride or Aripiprazole in the treatment of female patients with schizophrenia.Methods 80 female patients with schizophrenia which were treated in our hospital during January 2013 to December 2014 were selected,and then were randomly divided into Amisulpride group or Aripiprzole group,each group of 40 patients were treated with Amisulpride and Aripiprzole monotherapy,8-week course of treatment,respectively,one day before treatment,after the start of the first 4 weeks and 8 weeks observation and evaluation related treatment indicators. Results Both Amisulpride and Aripiprzole could significantly reduce schizophrenic patients PANSS scores（P〈0.05）,but no statistically significant difference between the two groups（P〉0.05）;Amisulpride treatment can lead to the patient serum prolactin levels increased,electrocardiogram QT prolongation,and the group Aripiprzole treatment this had little side effect. Aripiprzole group of patients overall incidence of adverse events was significantly lower than amisulpride（P〈0.05）.Conclusion Aripiprzole is more safer than Amisulpri as an antischizophrenic drug for female patients.

关 键 词：氨磺必利 阿立派唑 PANSS 泌乳素 QT间期 

分 类 号：R749.05[医药卫生—神经病学与精神病学]